Sitagliptin Phosphate Patent Expiration

Sitagliptin Phosphate is Used for managing glycemic control in adults with type 2 diabetes mellitus, often in combination with other medications like metformin or insulin. It was first introduced by Merck Sharp And Dohme Corp in its drug Januvia on Oct 16, 2006.


Sitagliptin Phosphate Patents

Given below is the list of patents protecting Sitagliptin Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Januvia US7326708

(Pediatric)

Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May 24, 2027 Merck Sharp Dohme
Januvia US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor Nov 24, 2026 Merck Sharp Dohme
Januvia US6699871

(Pediatric)

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan 26, 2023

(Expired)

Merck Sharp Dohme
Januvia US7125873

(Pediatric)

Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan 26, 2023

(Expired)

Merck Sharp Dohme
Januvia US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jul 26, 2022

(Expired)

Merck Sharp Dohme
Januvia US7125873 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jul 26, 2022

(Expired)

Merck Sharp Dohme
Januvia US6890898 Method of regulating glucose metabolism, and reagents related thereto Feb 02, 2019

(Expired)

Merck Sharp Dohme
Januvia US7078381 Method of regulating glucose metabolism, and reagents related thereto Feb 02, 2019

(Expired)

Merck Sharp Dohme
Januvia US7459428 Method of regulating glucose metabolism, and reagents related thereto Feb 02, 2019

(Expired)

Merck Sharp Dohme
Januvia US6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals Apr 24, 2017

(Expired)

Merck Sharp Dohme



Sitagliptin Phosphate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List